12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VX-787: Phase IIa started

Vertex disclosed in its 1Q12 earnings that it began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 2 doses...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >